MCID: CRY007
MIFTS: 50

Cryoglobulinemia, Familial Mixed

Categories: Bone diseases, Cardiovascular diseases, Genetic diseases, Nephrological diseases, Neuronal diseases, Rare diseases, Respiratory diseases

Aliases & Classifications for Cryoglobulinemia, Familial Mixed

MalaCards integrated aliases for Cryoglobulinemia, Familial Mixed:

Name: Cryoglobulinemia, Familial Mixed 56 71
Mixed Cryoglobulinemia 52 58 54 71
Essential Mixed Cryoglobulinemia 52 58 71
Cryoglobulinemic Vasculitis 52 58 71
Essential Cryoglobulinemia 52 58 71
Primary Cryoglobulinemia 52 58 71
Meltzer Syndrome 56 52
Familial Mixed Cryoglobulinemia 52

Characteristics:

Orphanet epidemiological data:

58
cryoglobulinemic vasculitis
Age of onset: All ages;

OMIM:

56
Inheritance:
autosomal dominant


HPO:

31
cryoglobulinemia, familial mixed:
Inheritance autosomal dominant inheritance


Classifications:

Orphanet: 58  
Rare neurological diseases
Rare circulatory system diseases
Rare renal diseases
Rare respiratory diseases
Rare systemic and rhumatological diseases


Summaries for Cryoglobulinemia, Familial Mixed

NIH Rare Diseases : 52 Cryoglobulinemic vasculitis occurs when the body makes a mix of abnormal immune system proteins called cryoglobulins. At temperatures less than 98.6 degrees Fahrenheit (normal body temperature), cryoglobulins become solid or gel-like and can block blood vessels. This causes a variety of health problems. Many people with cryoglobulins will not experience any symptoms. When symptoms occur, they may include purplish discolored skin (purpura ), weakness, joint pain, liver disease, and kidney problems. The underlying cause is unknown. Cryoglobulinemic vasculitis is typically associated with a chronic hepatitis C virus (HCV) infection. It is diagnosed based on the results of a clinical exam and the presence of cryoglobulins in the blood. Treatment varies based on the severity of symptoms and any underlying conditions.

MalaCards based summary : Cryoglobulinemia, Familial Mixed, also known as mixed cryoglobulinemia, is related to membranoproliferative glomerulonephritis and exanthem. An important gene associated with Cryoglobulinemia, Familial Mixed is IFNA1 (Interferon Alpha 1), and among its related pathways/superpathways are JAK-STAT signaling pathway and all-trans-Retinoic Acid Mediated Apoptosis. The drugs Sofosbuvir and Ledipasvir have been mentioned in the context of this disorder. Affiliated tissues include liver, b cells and skin, and related phenotypes are muscle weakness and fever

More information from OMIM: 123550

Related Diseases for Cryoglobulinemia, Familial Mixed

Diseases in the Cryoglobulinemia, Familial Mixed family:

Mixed Cryoglobulinemia Type Iii Type Ii Mixed Cryoglobulinemia

Diseases related to Cryoglobulinemia, Familial Mixed via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 342)
# Related Disease Score Top Affiliating Genes
1 membranoproliferative glomerulonephritis 30.8 TSLP IFNA1
2 exanthem 30.7 IFNA1 CD40LG
3 marginal zone b-cell lymphoma 30.2 CD5 CD40LG
4 lymphoplasmacytic lymphoma 30.2 CD5 CD40LG
5 splenomegaly 30.1 IFNA2 IFNA1
6 chickenpox 30.1 IFNA1 CD40LG
7 orchitis 30.0 IFNA2 CD40LG
8 leukemia, chronic lymphocytic 2 30.0 IGHM CD5
9 plasma cell neoplasm 30.0 CD5 CD40LG
10 cryoglobulinemia 29.9 TSLP IFNA2 IFNA1 CD5 CD40LG
11 anemia, autoimmune hemolytic 29.9 CD5 CD40LG
12 pyoderma 29.7 IFNA2 CD40LG
13 viral hepatitis 29.6 IFNA2 IFNA1 CD40LG
14 thrombocytopenic purpura, autoimmune 29.6 IFNA2 CD40LG
15 diarrhea 29.5 IFNA2 IFNA1 CD40LG
16 hepatitis d 29.5 IFNA2 IFNA1 CD40LG
17 herpes zoster 29.4 IFNA2 IFNA1 CD40LG
18 stomatitis 29.4 IFNA2 IFNA1 CD40LG
19 neutropenia 29.4 IFNA2 IFNA1 CD40LG
20 hepatitis a 29.3 IFNA2 IFNA1
21 hypothyroidism 29.2 IFNA2 IFNA1 ENO1
22 hairy cell leukemia 28.9 IFNA2 IFNA1 CD5 CD40LG
23 systemic lupus erythematosus 28.6 IFNA2 IFNA1 ENO1 CD5 CD40LG
24 leukemia, chronic lymphocytic 28.6 IGHM IFNA1 CD5 CD40LG BCR
25 glomerulopathy with fibronectin deposits 2 11.4
26 vasculitis 11.0
27 hepatitis c virus 10.8
28 hepatitis c 10.7
29 glomerulonephritis 10.6
30 purpura 10.6
31 neuropathy 10.5
32 peripheral nervous system disease 10.5
33 hepatitis 10.5
34 autoimmune disease 10.4
35 lymphoma, hodgkin, classic 10.3
36 lymphoma, non-hodgkin, familial 10.3
37 scleroderma, familial progressive 10.3
38 liver cirrhosis 10.3
39 polyarteritis nodosa 10.3
40 raynaud phenomenon 10.3
41 urticaria 10.2
42 thyroid carcinoma 10.2
43 marburg hemorrhagic fever 10.2 IFNA1 CD40LG
44 monkeypox 10.2 IFNA1 CD40LG
45 ebola hemorrhagic fever 10.2 IFNA1 CD40LG
46 myeloma, multiple 10.2
47 systemic scleroderma 10.2
48 b-cell non-hodgkin lymphoma 10.2
49 bell's palsy 10.2 IFNA1 CD40LG
50 eastern equine encephalitis 10.2 IFNA1 CD40LG

Graphical network of the top 20 diseases related to Cryoglobulinemia, Familial Mixed:



Diseases related to Cryoglobulinemia, Familial Mixed

Symptoms & Phenotypes for Cryoglobulinemia, Familial Mixed

Human phenotypes related to Cryoglobulinemia, Familial Mixed:

58 31 (show all 34)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 muscle weakness 58 31 hallmark (90%) Very frequent (99-80%) HP:0001324
2 fever 58 31 hallmark (90%) Very frequent (99-80%) HP:0001945
3 skin ulcer 58 31 hallmark (90%) Very frequent (99-80%) HP:0200042
4 petechiae 58 31 hallmark (90%) Very frequent (99-80%) HP:0000967
5 vasculitis 58 31 hallmark (90%) Very frequent (99-80%) HP:0002633
6 mediastinal lymphadenopathy 58 31 hallmark (90%) Very frequent (99-80%) HP:0100721
7 cutis marmorata 58 31 hallmark (90%) Very frequent (99-80%) HP:0000965
8 cryoglobulinemia 58 31 hallmark (90%) Very frequent (99-80%) HP:0100778
9 circulating immune complexes 58 31 hallmark (90%) Very frequent (99-80%) HP:0012224
10 splenomegaly 58 31 frequent (33%) Frequent (79-30%) HP:0001744
11 hepatomegaly 58 31 frequent (33%) Frequent (79-30%) HP:0002240
12 arthritis 58 31 frequent (33%) Frequent (79-30%) HP:0001369
13 proteinuria 58 31 frequent (33%) Frequent (79-30%) HP:0000093
14 renal insufficiency 58 31 frequent (33%) Frequent (79-30%) HP:0000083
15 arthralgia 58 31 frequent (33%) Frequent (79-30%) HP:0002829
16 hematuria 58 31 frequent (33%) Frequent (79-30%) HP:0000790
17 abdominal pain 58 31 frequent (33%) Frequent (79-30%) HP:0002027
18 myalgia 58 31 frequent (33%) Frequent (79-30%) HP:0003326
19 gangrene 58 31 frequent (33%) Frequent (79-30%) HP:0100758
20 glomerulopathy 58 31 frequent (33%) Frequent (79-30%) HP:0100820
21 gastrointestinal infarctions 58 31 frequent (33%) Frequent (79-30%) HP:0005244
22 viral hepatitis 58 31 frequent (33%) Frequent (79-30%) HP:0006562
23 sensorimotor neuropathy 58 31 frequent (33%) Frequent (79-30%) HP:0007141
24 mononeuropathy 58 31 frequent (33%) Frequent (79-30%) HP:0009831
25 gastrointestinal hemorrhage 58 31 occasional (7.5%) Occasional (29-5%) HP:0002239
26 keratoconjunctivitis sicca 58 31 occasional (7.5%) Occasional (29-5%) HP:0001097
27 peripheral neuropathy 58 Frequent (79-30%)
28 hypertension 31 HP:0000822
29 purpura 58 Very frequent (99-80%)
30 abnormality of the liver 58 Frequent (79-30%)
31 abnormality of blood and blood-forming tissues 31 HP:0001871
32 chronic kidney disease 31 HP:0012622
33 elevated serum creatinine 31 HP:0003259
34 anasarca 31 HP:0012050

Symptoms via clinical synopsis from OMIM:

56
Lab:
proteinuria
hematuria
elevated serum creatinine

Heme:
cryoglobulinemia

G U:
loss of renal function

Endocrine:
hypertension

Misc:
anasarca

Clinical features from OMIM:

123550

GenomeRNAi Phenotypes related to Cryoglobulinemia, Familial Mixed according to GeneCards Suite gene sharing:

26 (show all 20)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-105 9.7 IFNA1 IFNA2
2 Increased shRNA abundance (Z-score > 2) GR00366-A-115 9.7 BCR
3 Increased shRNA abundance (Z-score > 2) GR00366-A-127 9.7 IFNA2
4 Increased shRNA abundance (Z-score > 2) GR00366-A-14 9.7 IFNA1
5 Increased shRNA abundance (Z-score > 2) GR00366-A-145 9.7 IFNA1
6 Increased shRNA abundance (Z-score > 2) GR00366-A-167 9.7 IFNA2
7 Increased shRNA abundance (Z-score > 2) GR00366-A-168 9.7 BCR IFNA1 IFNA2
8 Increased shRNA abundance (Z-score > 2) GR00366-A-175 9.7 IFNA1
9 Increased shRNA abundance (Z-score > 2) GR00366-A-184 9.7 IFNA2
10 Increased shRNA abundance (Z-score > 2) GR00366-A-209 9.7 IFNA1
11 Increased shRNA abundance (Z-score > 2) GR00366-A-215 9.7 BCR
12 Increased shRNA abundance (Z-score > 2) GR00366-A-25 9.7 IFNA2
13 Increased shRNA abundance (Z-score > 2) GR00366-A-29 9.7 BCR IFNA2
14 Increased shRNA abundance (Z-score > 2) GR00366-A-61 9.7 IFNA1
15 Increased shRNA abundance (Z-score > 2) GR00366-A-62 9.7 IFNA2
16 Increased shRNA abundance (Z-score > 2) GR00366-A-78 9.7 IFNA1
17 Increased shRNA abundance (Z-score > 2) GR00366-A-79 9.7 IFNA1
18 Increased shRNA abundance (Z-score > 2) GR00366-A-8 9.7 IFNA1
19 Increased shRNA abundance (Z-score > 2) GR00366-A-85 9.7 BCR
20 Increased shRNA abundance (Z-score > 2) GR00366-A-91 9.7 BCR

Drugs & Therapeutics for Cryoglobulinemia, Familial Mixed

Drugs for Cryoglobulinemia, Familial Mixed (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 29)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Sofosbuvir Approved Phase 2, Phase 3 1190307-88-0 45375808
2
Ledipasvir Approved Phase 2, Phase 3 1256388-51-8 67505836
3 Antiviral Agents Phase 2, Phase 3
4 Anti-Infective Agents Phase 2, Phase 3
5 Ledipasvir, sofosbuvir drug combination Phase 2, Phase 3
6
Aldesleukin Approved Phase 1, Phase 2 85898-30-2, 110942-02-4
7
Lactitol Approved, Investigational Phase 1, Phase 2 585-88-6, 585-86-4 493591
8
rituximab Approved Phase 2 174722-31-7 10201696
9
Prednisone Approved, Vet_approved Phase 2 53-03-2 5865
10 Immunoglobulins Phase 2
11 Antibodies Phase 2
12 Antibodies, Monoclonal Phase 2
13 Anti-HIV Agents Phase 1, Phase 2
14 Anti-Retroviral Agents Phase 1, Phase 2
15 Antirheumatic Agents Phase 2
16 Antineoplastic Agents, Immunological Phase 2
17 Immunologic Factors Phase 2
18 Hormones Phase 2
19 Antineoplastic Agents, Hormonal Phase 2
20 Hormone Antagonists Phase 2
21 glucocorticoids Phase 2
22 Anti-Inflammatory Agents Phase 2
23
Betamethasone Approved, Vet_approved 378-44-9 9782
24
Ribavirin Approved 36791-04-5 37542
25 Respiratory System Agents
26 Anti-Asthmatic Agents
27 Antimetabolites
28 interferons
29 Liver Extracts

Interventional clinical trials:

(show all 13)
# Name Status NCT ID Phase Drugs
1 Efficacy of All-Oral Anti-Viral Therapy for Symptomatic Hepatitis C Virus Infection-Related Cryoglobulinemia Completed NCT02825212 Phase 2, Phase 3 Harvoni
2 Rituximab (Anti-CD20) for the Treatment of Hepatitis C Associated Cryoglobulinemic Vasculitis Completed NCT00029107 Phase 2 Rituximab
3 ANRS HC 21 VASCU IL-2, Evaluation of the Cellular Immune Response, Clinical Efficacy and Tolerance After IL-2 Therapy in HCV-related Vasculitis Patients, Resistant to Conventional Therapy. Completed NCT00574652 Phase 1, Phase 2 Proleukin
4 Multicenter Randomized Double-blind Study Comparing the Efficacy and Safety of Rituximab in Combination With Corticosteroids to Corticosteroids Plus Placebo in the Treatment of Non-infectious Active Mixed Cryoglobulinemia Vasculitis Terminated NCT02556866 Phase 2 rituximab;Prednisone;Placebo
5 Direct Antiviral Agents for Hepatitis C Virus-associated Cryoglobulinaemia Vasculitis Unknown status NCT02856243 new antiviral therapy
6 Different Histopathological Patterns in Patients With HCV Nephropathy Unknown status NCT03476031
7 Pattern of Skin Manifestations in Chronic Hepatitis c Virus Patients Before and After Direct Acting Anti Viral Drugs: Prospective Controlled Clinical Trial Unknown status NCT03170076
8 Randomized Controlled Study of Off-Label Use of Ribavirin in Management of Mucocutaneous Extrahepatic Manifestations of HCV Infection Unknown status NCT02261662 Ribavirin;Betamethasone
9 Benefit of Direct-acting Antiviral Therapy in Hepatitis C Virus (HCV) Monoinfected and HIV-HCV Coinfected Patients With Mixed Cryoglobulinemia Completed NCT03342261 DAA treatment
10 Characterization of Clonal B Cell Populations in HCV Infection Completed NCT00435201
11 Clinical Transcriptomics in Systemic Vasculitis (CUTIS) Recruiting NCT03004326
12 Long-term Hepatic and Extra-hepatic Outcomes of Chronic Hepatitis C Patients Post Sofosbuvir-based Interferon-free Treatment (LONGHEAD Study) Recruiting NCT03042520
13 Study to Determine the Hepatitis C Virus Infection Prevalence Among Patients Attended Primarily for Vasculitis and Other Potential Extrahepatic Manifestations Recruiting NCT03693586

Search NIH Clinical Center for Cryoglobulinemia, Familial Mixed

Genetic Tests for Cryoglobulinemia, Familial Mixed

Anatomical Context for Cryoglobulinemia, Familial Mixed

MalaCards organs/tissues related to Cryoglobulinemia, Familial Mixed:

40
Liver, B Cells, Skin, Kidney, Thyroid, Bone, Bone Marrow

Publications for Cryoglobulinemia, Familial Mixed

Articles related to Cryoglobulinemia, Familial Mixed:

(show top 50) (show all 1350)
# Title Authors PMID Year
1
Inheritance of mixed cryoglobulinemia. 56 61
7294022 1981
2
A shared cryoglobulin antigen in familial cryoglobulinemia. 56
6794362 1981
3
Cryoglobulinemia--a clinical and laboratory study. II. Cryoglobulins with rheumatoid factor activity. 56
4956871 1966
4
Cryoglobulinemia. An inherited molecular disease? 56
13977780 1963
5
Interferon therapy in rheumatic diseases: state-of-the-art 2010. 54 61
20061957 2010
6
Immune signatures in human PBMCs of idiotypic vaccine for HCV-related lymphoproliferative disorders. 61 54
20170491 2010
7
B-cell depletion in the treatment of mixed cryoglobulinemia. 54 61
17936212 2007
8
Thymic stromal lymphopoietin transgenic mice develop cryoglobulinemia and hepatitis with similarities to human hepatitis C liver disease. 61 54
17322382 2007
9
Treatment of hepatitis C virus-associated inflammatory polyneuropathy with pegylated interferon-alpha and ribavirin. 61 54
17206084 2007
10
Overexpression of complement inhibitor Crry does not prevent cryoglobulin-associated membranoproliferative glomerulonephritis. 54 61
15086460 2004
11
Interferon plus ribavirin in patients with hepatitis C virus positive mixed cryoglobulinemia resistant to interferon. 54 61
12913934 2003
12
Monoclonal antibody treatment of mixed cryoglobulinemia resistant to interferon alpha with an anti-CD20. 54 61
12506023 2003
13
Growth factor expression in a murine model of cryoglobulinemia. 61 54
12631122 2003
14
Serum interferon (IFN)-neutralizing antibodies and bioactivities of IFNs in patients with severe type II essential mixed cryoglobulinemia. 54 61
12522042 2003
15
[Hepatitis-C-virus-associated cryoglobulinemia. Pathogenesis, diagnosis and treatment]. 54 61
12386793 2002
16
Cryoglobulinemic glomerulonephritis in thymic stromal lymphopoietin transgenic mice. 61 54
11733384 2001
17
[Characterization of cryoglobulin, M protein, low molecular weight IgM in a patient with chronic hepatitis C and type II mixed cryoglobulinemia]. 61 54
11769562 2001
18
Cryoglobulinemia associated with Purtscher-like retinopathy. 61 54
11384584 2001
19
Treatment of refractory, symptomatic, hepatitis C virus related mixed cryoglobulinemia with ribavirin and interferon-alpha. 54 61
10990230 2000
20
Pre-malignant and malignant lymphoproliferations in an HCV-infected type II mixed cryoglobulinemic patient are sequential phases of an antigen-driven pathological process. 61 54
10861476 2000
21
[Development of cyroglobulinemia and polyneuropathy in a chronic myeloid leukemia patient during interferon-alpha treatment]. 61 54
10355142 1999
22
New concepts in treatment protocols for severe systemic vasculitis. 54 61
9894629 1999
23
Hepatitis C virus and immunoglobulin gene rearrangements: an early step in lymphomagenesis? 54 61
9858787 1998
24
Alpha-enolase is a renal-specific antigen associated with kidney involvement in mixed cryoglobulinemia. 61 54
9444422 1997
25
Exacerbation of peripheral neuropathy during alpha-interferon therapy in a patient with mixed cryoglobulinemia and hepatitis B virus infection. 61 54
8877939 1996
26
Cryoglobulinemia in hepatitis C virus chronic active hepatitis: effects of interferon-alpha therapy. 61 54
8877728 1996
27
Regression of monoclonal B-cell expansion in patients affected by mixed cryoglobulinemia responsive to alpha-interferon therapy. 54 61
8640712 1996
28
Treatment of mixed cryoglobulinemia with recombinant interferon alpha and adjuvant therapies. A prospective study on 20 patients. 61 54
8760684 1996
29
Effects of two different alpha-interferon regimens on clinical and virological findings in mixed cryoglobulinemia. 61 54
8730503 1995
30
Monoclonal IgM rheumatoid factor secreted by CD5-negative B cells during mixed cryoglobulinemia. Evidence for somatic mutations and intraclonal diversity of the expressed VH region gene. 54 61
7527818 1995
31
Hepatitis C virus: the nephrologist's view. 61 54
7810528 1995
32
Resistance to recombinant alpha interferon therapy in idiopathic mixed cryoglobulinemia: reinduction of remission by natural alpha interferon both in antibody-positive and -negative patients. 54 61
7863814 1994
33
Interferon-alpha in mixed cryoglobulinemia patients: a randomized, crossover-controlled trial. 54 61
8382969 1993
34
CD5 negative IGM rheumatoid factor B cells in B-chronic lymphocytic leukemia and benign mixed cryoglobulinemia. 61 54
1282064 1992
35
Complete sequence of the genes encoding the VH and VL regions of low- and high-affinity monoclonal IgM and IgA1 rheumatoid factors produced by CD5+ B cells from a rheumatoid arthritis patient. 54 61
1718404 1991
36
The majority of peripheral blood monoclonal IgM secreting cells are CD5 negative in three patients with mixed cryoglobulinemia. 54 61
1707697 1991
37
Safety and effectiveness of biosimilar of Rituximab CT-P10 in the treatment of cryoglobulinemic vasculitis: the MARBLe study (Mixed cryoglobulinemiA Rituximab BiosimiLar). 61
32524338 2020
38
A case of glomerulonephritis caused by brucellosis. 61
32508259 2020
39
Rituximab-associated Vasculitis Flare: Incidence, Predictors, and Outcome. 61
31371658 2020
40
Hepatitis C virus- related cryoglobulinemic vasculitis: A review of the role of the new direct antiviral agents (DAAs) therapy. 61
32540448 2020
41
Membranoproliferative Glomerulonephritis and Mixed Cryoglobulinemia as a Form of Presentation of Visceral Leishmaniasis. 61
32459796 2020
42
Cryoglobulinemia after the era of chronic hepatitis C infection. 61
32521323 2020
43
Biomarkers of minimal residual disease in rituximab-treated patients with mixed cryoglobulinemia. 61
32333692 2020
44
Sentinel biomarkers in HCV positive patients with mixed cryoglobulinemia. 61
31669506 2020
45
Impact of mixed cryoglobulinemia on patients with spontaneous hepatitis C virus clearance: A 13-year prospective cohort study. 61
31782138 2020
46
Graves' disease: Epidemiology, genetic and environmental risk factors and viruses. 61
32107168 2020
47
Cutaneous manifestations of HAV, HBV, HCV. 61
31804053 2019
48
Type II mixed cryoglobulinemia following influenza and pneumococcal vaccine administration. 61
31687464 2019
49
Understanding the Cryoglobulinemias. 61
31741077 2019
50
Positive acute viral infection markers, autoimmune disease and type II mixed cryoglobulinemia: a rare concurrence. 61
31780611 2019

Variations for Cryoglobulinemia, Familial Mixed

Expression for Cryoglobulinemia, Familial Mixed

Search GEO for disease gene expression data for Cryoglobulinemia, Familial Mixed.

Pathways for Cryoglobulinemia, Familial Mixed

Pathways related to Cryoglobulinemia, Familial Mixed according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
11.53 TSLP IFNA2 IFNA1
2 10.3 IFNA2 IFNA1

GO Terms for Cryoglobulinemia, Familial Mixed

Cellular components related to Cryoglobulinemia, Familial Mixed according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 external side of plasma membrane GO:0009897 9.13 IGHM CD5 CD40LG
2 extracellular space GO:0005615 9.1 TSLP IGHM IFNA2 IFNA1 ENO1 CD40LG

Biological processes related to Cryoglobulinemia, Familial Mixed according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 type I interferon signaling pathway GO:0060337 9.48 IFNA2 IFNA1
2 humoral immune response GO:0006959 9.46 IFNA2 IFNA1
3 T cell costimulation GO:0031295 9.43 CD5 CD40LG
4 response to exogenous dsRNA GO:0043330 9.4 IFNA2 IFNA1
5 positive regulation of interleukin-10 production GO:0032733 9.37 TSLP CD40LG
6 T cell activation involved in immune response GO:0002286 9.32 IFNA2 IFNA1
7 positive regulation of peptidyl-serine phosphorylation of STAT protein GO:0033141 9.26 IFNA2 IFNA1
8 natural killer cell activation involved in immune response GO:0002323 9.16 IFNA2 IFNA1
9 B cell differentiation GO:0030183 9.13 IFNA2 IFNA1 CD40LG
10 B cell proliferation GO:0042100 8.8 IFNA2 IFNA1 CD40LG

Molecular functions related to Cryoglobulinemia, Familial Mixed according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine receptor binding GO:0005126 9.16 IFNA2 IFNA1
2 type I interferon receptor binding GO:0005132 8.96 IFNA2 IFNA1
3 cytokine activity GO:0005125 8.92 TSLP IFNA2 IFNA1 CD40LG

Sources for Cryoglobulinemia, Familial Mixed

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....